The provided text contains only the editorial board information for the journal and does not include any clinical study data or findings.
For decades, lifelong treatment with low-dose aspirin has remained a key strategy for secondary prevention in chronic coronary syndrome (CCS). 1 In this setting, aspirin reduces the risk of cardiovascular events by up to 31%, 1 however marked interindividual variability in platelet inhibition from aspirin treatment is well documented among patients with CCS. 2 In patients receiving aspirin for secondary prevention, approximately 25% show reduced effect assessed biochemically, and up to 15% of patients experience a recurrent event within 2 years. 3 Reduced aspirin effect is associated with a higher risk of future events. 4 Aspirin irreversibly acetylates cyclooxygenase 1 (COX1), thus blocking the conversion of arachidonic acid to thromboxane A2 (TXA), a potent platelet activator, and aspirin thereby irreversibly inhibits platelet function throughout their lifespan. 5 TXA is rapidly hydrolyzed to yield the more stable metabolite thromboxane B2 (TXB2). Serum TXB2 thereby reflects the enzymatic activity of COX1, and measurement of serum TXB2 provides the most direct evaluation of aspirin's pharmacodynamic effect. 5 We sought to identify independent determinants of aspirin-induced COX1-inhibition, assessed with serum TXB2, in a large, well-defined cohort of CCS patients receiving 75 mg of aspirin daily. Received: 19 March 2026 Accepted after revision: 11 May 2026 Accepted Manuscript online: 18 May 2026 Article published online: 26 May 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Friis et al. (Mon,) conducted a other in chronic coronary syndrome. aspirin was evaluated. The provided text contains only the editorial board information for the journal and does not include any clinical study data or findings.